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The relationships among treatment regimens, plasma human immunodeficiency virus (HIV)
RNA levels, and resistance mutations to saquinavir (codons 48 and 90) and zidovudine (codon
215) were examined in a cohort of 144 patients from the AIDS Clinical Trials Group 229
study. After 24–40 weeks of therapy, no patients who had received the two-drug combination
(zidovudine plus saquinavir) had only codon 48 mutations, 45.8% had only codon 90 mu-
tations, and 8.3% had both codon 48 and 90 mutations. Mutations developed by patients
who had received the three-drug combination (zidovudine and zalcitabine plus saquinavir)
were codon 48 alone in 1.4%, codon 90 alone in 33.3%, and both codons 48 and 90 in 4.2%.
The difference between the groups showed a trend toward reduced mutations with three versus
two drugs but did not reach significance ( , two-sided x2). Higher baseline HIV RNAP 5 .11
levels correlated with the development of protease mutations. Mutations at codon 215 were
present in 82% of all patients at baseline and in 87% after therapy.
Combination therapy is currently the standard of care in
human immunodeficiency virus (HIV)–infected patients [1, 2].
Due to the highly effective nature of potent antiretroviral drug
regimens, insight into the development of resistance mutations
and loss of plasma HIV RNA suppression may require large,
expensive studies with prolonged periods of follow-up. Study
of earlier clinical trials performed with less potent combinations
of drugs and in drug-experienced patients, in whom drug re-
sistance and failure developed more rapidly than with antire-
troviral-naive patients, may provide insight into some of the
causes leading to combination therapy failure [3].
The importance of suppressing plasma HIV RNA with com-
bination therapy to obtain a more durable response has
emerged from recent studies [4, 5]. This suppression reflects
reduced viral replication, thus minimizing the opportunities for
HIV to develop drug resistance mutations [5, 6]. Although the
correlation between virus load reduction and duration of re-
sponse and improved prognosis has been well documented in
large studies [5, 7], fewer data are available about these features
and protease drug resistance mutations.
Combinations including a greater number of antiretroviral
agents are now commonly prescribed due to their clinical suc-
cess [8–10]. Although three- and four-drug combinations are
being studied and used [10, 11], the degree to which the addition
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of a third agent to a double drug combination actually reduces
the rate at which resistance mutations develop has not been
well studied.
We sought to gain insight into these questions by examining
the relationships among treatment regimens, plasma HIV RNA
virus load levels, and the presence of resistance mutations to
saquinavir and zidovudine in a large cohort of patients from
the AIDS Clinical Trials Group (ACTG) 229 study in which
zidovudine-experienced patients were randomized to receive
zidovudine plus zalcitabine, zidovudine plus saquinavir, or zi-
dovudine and zalcitabine plus saquinavir.
Methods
Patients. ACTG 229 was a double-blind randomized study
that enrolled 302 patients with a baseline CD4 T cell count of
50–300/mL and at least 6 months of prior zidovudine therapy to
receive one of three treatments, zidovudine plus zalcitabine, zi-
dovudine plus saquinavir (hard-gel capsule), or zidovudine and
zalcitabine plus saquinavir (hard-gel capsule). Patients had a me-
dian of 27 months of prior zidovudine therapy. Of the 302 enrolled,
285 completed the initial 24 weeks of study [3]. We examined all
available stored samples from the zidovudine plus saquinavir and
zidovudine and zalcitabine plus saquinavir arms of the study for
resistance mutations to saquinavir and zidovudine. Patients from
the non–saquinavir-containing zidovudine plus zalcitabine arm
were not studied, as they were not expected to develop saquinavir
resistance mutations.
Mutations. Mutations to saquinavir at codons 48 (G to V)
and 90 (L to M) in the HIV-1 protease gene were determined from
frozen plasma from samples taken at baseline and after 24–40
weeks of therapy. The presence of a wild type (WT) or mutant
250 Schapiro et al. JID 1999;179 (January)
Table 1. Mutations at codons 48 and 90 in patients receiving either zidovudine (ZDV) plus saquinavir (SAQ)
or ZDV and zalcitabine (ddC) plus SAQ.
Baseline >24 weeks
Codon 48 Codon 90 Codons 48 and 90 Codon 48 Codon 90 Codons 48 and 90
ZDV 1 SAQ 0% (0/60) 0% (0/60) 0% (0/60) 0% (0/72) 45.8% (33/72) 8.3% (6/72)
ZDV 1 ddC 1 SAQ 0% (0/57) 0% (0/57) 0% (0/57) 1.4% (1/72) 33.3% (24/72) 4.2% (3/72)
All patients 0% (0/117) 0% (0/117) 0% (0/117) 0.7% (1/144) 39.6% (57/144) 6.3% (9/144)
Figure 1. Changes in plasma human immunodeficiency virus RNA levels in patients receiving therapy with either zidovudine plus saquinavir
( ) or zidovudine and zalcitabine plus saquinavir ( ).ZDV 1 SAQ ZDV 1 ddC 1 SAQ
(MU) genotype was determined using a selective polymerase chain
reaction method as previously described [12]. In addition, the pres-
ence of the codon 215 mutation to zidovudine was determined by
a similar technique [13].
Statistical analysis. Plasma HIV RNA levels and CD4 T cell
counts had been previously determined for each patient as part of
the ACTG 229 clinical trial [3]. These data were obtained from the
ACTG 229 database and were correlated with the presence of WT
or MU genotype for the resistance mutations studied.
Results
Samples from 144 of the 149 patients who remained on ther-
apy were analyzed for mutations at codons 48 and 90 of the
protease gene after 24–40 weeks of treatment. Of these patients,
135 were at week 24, 7 at week 32, and 2 at week 40. Seventy-
two patients had received treatment with zidovudine plus sa-
quinavir and an equal number had received zidovudine and
zalcitabine plus saquinavir. In addition, for 60 patients in the
zidovudine plus saquinavir and for 57 in the zidovudine and
zalcitabine plus saquinavir groups, baseline samples taken be-
fore therapy started were also analyzed. All baseline samples
in both treatment groups were WT for codons 48 and 90 (table
1).
Following therapy with the two-drug combination in 72 pa-
tients, none had developed the codon 48 mutation alone, 45.8%
(33) had developed the codon 90 mutation alone, and 8.3% (6)
had developed both codons 48 and 90 mutations. Of the 72
patients receiving the triple combination, 1.4% (1 patient) had
developed the codon 48 mutation alone, 33.3% (24) had de-
veloped the codon 90 mutation alone, and 4.2% (3) had de-
veloped both codon 48 and 90 mutations. The rate of mutations
developing after treatment for both groups ( ) combinedn 5 144
was 0.7% (1 patient), 39.6% (57), and 6.3% (9) for codon 48
alone, 90 alone, and 48 and 90 together, respectively. The de-
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Figure 2. Changes in plasma human immunodeficiency virus (HIV) RNA levels in patients who developed codon 90 mutation (MU) to saquinavir
in their HIV protease gene following 24–40 weeks of therapy and in those who retained wild type (WT) at codon 90.
velopment of the codon 90 mutation showed a trend toward
statistical significance for the two-drug (33/72, 45.8%) versus
the three-drug (24/72, 33.3%) regimen ( , two-sided x2).P 5 .11
The total number of mutations to saquinavir (codons 48 and
90) also showed a trend toward statistical significance for the
two-drug (39/72, 54.2%) than for the three-drug (28/72, 38.9%)
regimen ( , two-sided x2).P 5 .10
Samples from 112 patients in both groups were also analyzed
for mutations in the reverse transcriptase gene at codon 215,
both before and after therapy. Mutations at codon 215 were
present in 82% (92 patients) at baseline and in 87% (97) after
therapy. There was no statistical difference in the proportion
with codon 215 mutations before or after therapy between the
zidovudine plus saquinavir and the zidovudine and zalcitabine
plus saquinavir groups.
As was seen in the parent study, the changes in plasma HIV
virus load for the group receiving zidovudine plus saquinavir
and that receiving zidovudine and zalcitabine plus saquinavir
showed a greater reduction for the three- versus two-drug com-
bination (figure 1). There was no statistical difference in the
baseline plasma HIV RNA values between the treatment
groups.
Changes in plasma HIV RNA were plotted for patients who
developed the codon 90 mutation following therapy and for
those who did not (figure 2). The group in which the codon 90
mutation developed had a higher mean baseline plasma HIV
RNA level (5.13 log RNA copies/mL, SD 0.58) than the group
in which the mutation did not develop (4.79 log RNA copies/
mL, SD 0.66) ( ). The maximal reduction in plasma HIVP ! .01
RNA in the patients developing the mutation was seen at week
4 and was 0.36 log RNA copies/mL. In the group not devel-
oping the codon 90 mutation, the maximal reduction was at
week 8 and was 0.45 log RNA copies/mL. The plasma HIV
RNA levels remained consistently lower in the group that did
not develop the 90 mutation through week 48, although there
was no statistical difference in the magnitude of the reduction
from baseline between the 2 groups
The effect of the baseline reverse transcriptase codon 215
mutational status on the subsequent development of the pro-
tease codon 90 mutation was examined. There was no sta-
tistical difference in the rate at which mutations at codon 90
developed in patients with or without the codon 215 mutation
at baseline.
Discussion
We studied the rate of development of key resistance mu-
tations to saquinavir and zidovudine in highly zidovudine-
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experienced patients receiving either a two-drug combination
(zidovudine plus saquinavir) or a triple-drug combination (zi-
dovudine and zalcitabine plus saquinavir). Although the dif-
ference did not reach statistical significance ( ), there wasP 5 .11
a trend toward a higher rate of development of mutations to
saquinavir in patients receiving the two- versus the three-drug
combination.
The number of mutations developing to saquinavir in this
study was relatively high, considering that the great majority
of patients were assayed after 24 weeks of therapy. In a review
of early saquinavir-containing studies, Jacobsen et al. [14]
found that 33% of patients on monotherapy had developed
mutations by 4–6 months and 12.5%–63% after 7–12 months.
Of interest, in a small study of overlapping patients from ACTG
229, Jacobsen et al. [14] reported that 12% and 22% of patients
in the triple-drug combination group had mutations after 4–6
and 7–12 months, respectively. The differences between our
findings and those previously reported may be due to the small
number of patients previously studied (25 at 4–6 months and
18 at 7–12 months) and the specimens assayed (peripheral
blood mononuclear cells vs. plasma) in the previous study. The
high rate of saquinavir mutations in our study also may be
related to the very high rate of baseline codon 215 mutations
to zidovudine. Since most of the patients were already resistant
to zidovudine at the start of therapy, little or no reduction in
virus load was likely produced by the zidovudine component
of the regimen, allowing mutations to saquinavir to develop at
a higher rate.
The two-drug combination ( ) resulted in a total of 33n 5 72
(46%) patients developing the codon 90 mutation compared
with 24 (33%) of 72 receiving three drugs ( ). This trendn 5 72
may not have reached statistical significance due to the high
rate of codon 90 mutation in both groups. This may be due to
the high baseline virus load, to suboptimal exposure to saquin-
avir achieved with the standard dose used in this study, and to
the high rate of baseline codon 215 mutations. Therefore, many
patients in the triple-drug combination arm were essentially
receiving active antiretrovirals in the form of zalcitabine and
low-exposure saquinavir. This, coupled with the high virus load,
would produce partial selective pressure on a highly replicating
virus, a situation believed to result in high mutational rates [12,
15]. More potent antiretroviral regimens with greater drug ex-
posure in the setting of less baseline drug resistance would be
more likely to ultimately show benefit for three- versus two-
drug regimens in reducing the development of mutations [4, 7].
The higher baseline and nadir virus load found in patients
who developed the codon 90 mutation compared with those
who did not supports the concept that higher viral replication
increases the potential for resistance mutations to develop [15].
Recently, Kempf et al. [16] showed a strong correlation between
the nadir of HIV RNA obtained after initiation of antiretroviral
therapy and the duration of virus load suppression [16]. Lower
nadirs resulted in a more durable response. Our results showing
that lower nadirs result in a lower mutational rate would sup-
port their findings, as the lower mutational rate links the lower
nadir to a more durable response.
In summary, we believe the results of this comprehensive
mutational analysis of patients receiving dual versus triple com-
bination therapy help substantiate our understanding of the
mechanisms leading to drug resistance and support the current
guidelines of administering triple combinations to obtain max-
imal viral suppression [1, 2].
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